Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 1/2 3Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Multiple Myeloma 1Hematologic Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Leflunomide × Clear all
NCT03709446 2026-03-19

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
Breast

Breast Diseases, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04532372 2024-07-03

Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

City of Hope Medical Center

Phase 1/2 Completed
2 enrolled 7 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT02509052 2023-10-10

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Completed
12 enrolled 21 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡